866-997-4948(US-Canada Toll Free)

Liquid Biopsy Market, Global Analysis by Cancer (Lung, Breast, Colorectal, etc), Products, Circulating Biomarkers, Sample, Clinical Application, Regions & Companies

Published By :

Renub Research

Published Date : Aug 2018

Category :

In Vitro Diagnostics

No. of Pages : 138 Pages

Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.

Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient’s tumor and provide clues about the treatment that a patient’s needs.

Renub Research report titled “Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen)” provides a complete analysis of Global Liquid Biopsy Market.

By Cancer – Lung Cancer Controls the Liquid Biopsy Market

The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market.

By Product – Majority of Liquid Biopsy Market held by Kits & Consumables 

The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments.

By Circulating Biomarkers 

  • The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share

By Sample – Plasma/Serum accounts for the maximum market 

  • In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.

By Clinical Application – Screening Purpose leads the Liquid Biopsy Market

The report studies the market of the following clinical application segments: Monitoring, Prognosis, Theranostics & Screening.

By Region – North America and Europe will drive the Liquid Biopsy Market
 
North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market.

Companies Analysis

Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report.

All the 9 Companies Studied in the Report have been Studied from 3 Points 

  • Company Overview    
  • Product Portfolio
  • Financial Insight

This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.

By Cancer 

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others 

By Product

  • Kits & Consumables
  • Instruments
  • Services

By Circulating Biomarkers

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Exosomes

By Sample 

  • Plasma/Serum
  • Urine
  • Others

By Clinical Application

  • Monitoring
  • Prognosis
  • Theranostics
  • Screening

By Regions

  • North America
  • Europe
  • Asia-Pacific 
  • Latin America
  • Middle East/Africa

By Companies

  • Thermo Fisher Scientific Inc.
  • Roche Diagnostics
  • Bio-Rad Laboratories Inc.
  • Biocept Inc.
  • Biocartis
  • Myriad Genetics, Inc.
  • Genomic Health
  • NeoGenomics Laboratories
  • Qiagen

Table of Content

1. Executive Summary

2. Global - Liquid Biopsy Market

3. Market Share – Global Liquid Biopsy
3.1 By Region
3.2 By Cancer
3.3 By Product
3.4 By Circulating Biomarkers

4. Region - Liquid Biopsy Market
4.1 North America
4.2 Europe
4.3 Asia-Pacific
4.4 Latin America
4.5 Middle East & Africa

5. Cancer - Liquid Biopsy Market
5.1 Lung Cancer
5.2 Breast Cancer
5.3 Colorectal Cancer
5.4 Prostate Cancer
5.5 Others

6. By Product - Liquid Biopsy Market
6.1 Kits & Consumables
6.2 Instruments
6.3 Services

7. Circulating Biomarkers - Liquid Biopsy Market
7.1 Circulating Tumor Cells (CTCs)
7.2 Circulating Tumor DNA (ctDNA)
7.3 Exosomes

8. By Clinical Application - Liquid Biopsy Market
8.1 Monitoring
8.2 Prognosis
8.3 Theranostics
8.4 Screening

9. By Sample - Liquid Biopsy Market
9.1 Plasma / Serum
9.2 Urine
9.3 Others

10. Thermo Fisher Scientific Inc – Company Analysis
10.1 Product Portfolio
10.1.1 Financial Insight

11 Roche Diagnostics – Company Analysis
11.1 Product Portfolio
11.1.1 Financial Insight

12. Bio-Rad Laboratories Inc – Company Analysis
12.1 Product Portfolio
12.1.1 Financial Insight

13. Biocept, Inc. – Company Analysis
13.1 Product Portfolio
13.2 Financial Insight

14. Biocartis – Company Analysis
14.1 Product Portfolio
14.2 Financial Insight

15. Myriad Genetics, Inc – Company Analysis
15.1 Product Portfolio
15.2 Financial Insight

16. Genomic Health – Company Analysis
16.1 Product Portfolio
16.2 Financial Insight

17. NeoGenomics Laboratories – Company Analysis
17.1 Product Portfolio
17.2 Financial Insight

18. Qiagen – Company Analysis
18.1 Product Portfolio
18.2 Financial Insight

19. Growth Drivers
19.1 Real-Time Evaluation, Convenient and Accuracy
19.2 Increasing Demand for Minimally-Invasive Biopsy Techniques
19.3 Technical Advancement & Personalized Therapies

20. Challenges
20.1 Barriers for Liquid Biopsies
20.2 High Cost with Uncertain or Limited Reimbursement for Liquid Biopsy

List of Table

Table 4-1: Estimated number of people living with cancer: by nation, at the end of 2010, 2015, 2020 and 2030    
Table 4-2: Cancer Statistics Japan - 2017

List of Chart

Figure 2?1: Global – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 2?2: Global – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 3?1: By Region – Liquid Biopsy Market Share (%), 2013 – 2017
Figure 3?2: By Region – Forecast for Liquid Biopsy Market Share (%), 2018 – 2024
Figure 3?3: By Cancer – Liquid Biopsy Market Share (%), 2013 - 2017
Figure 3?4: By Cancer – Forecast for Liquid Biopsy Market Share (%), 2018 – 2024
Figure 3?5: By Product – Liquid Biopsy Market Share (%), 2013 – 2017
Figure 3?6: By Product – Forecast for Liquid Biopsy Market Share (%), 2018 – 2024
Figure 3?7: By Circulating Biomarkers – Liquid Biopsy Market Share (%), 2013 – 2017
Figure 3?8: By Circulating Biomarkers – Forecast for Liquid Biopsy Market Share (%), 2018 – 2024
Figure 4?1: United State Cancers by rates of New Cancer Cases (Male & Female) - 2015
Figure 4?2: United State Cancers by rates of Cancer Deaths (Male & Female) - 2015
Figure 4?3: North America – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 4?4: North America – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 4?5: Europe – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 4?6: Europe – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 4?7: Asia-Pacific – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 4?8: Asia-Pacific – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 4?9: Latin America – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 4?10: Latin America – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 4?11: Middle East & Africa – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 4?12: Middle East & Africa – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 5?1: Lung Cancer – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 5?2: Lung Cancer – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 5?3: Breast Cancer – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 5?4: Breast Cancer – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 5?5: Colorectal Cancer – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 5?6: Colorectal Cancer – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 5?7: Prostate Cancer – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 5?8: Prostate Cancer – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 5?9: Others – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 5?10: Others – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 6?1: Kits & Consumables – Liquid Biopsy Market (Million US$), 2013 - 2017
Figure 6?2: Kits & Consumables – Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
Figure 6?3: Instruments – Liquid Biopsy Market (Million US$), 2013 - 2017
Figure 6?4: Instruments – Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
Figure 6?5: Services – Liquid Biopsy Market (Million US$), 2013 - 2017
Figure 6?6: Services – Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
Figure 7?1: CTCs – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 7?2: CTCs – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 7?3: ctDNA – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 7?4: ctDNA – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 7?5: Exosomes – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 7?6: Exosomes – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 8?1: Monitoring – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 8?2: Monitoring – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 8?3: Prognosis – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 8?4: Prognosis – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 8?5: Theranostics – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 8?6: Theranostics – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 8?7: Screening – Liquid Biopsy Market (Million US$), 2013 – 2017
Figure 8?8: Screening – Forecast for Liquid Biopsy Market (Million US$), 2018 – 2024
Figure 9?1: Plasma/Serum – Liquid Biopsy Market (Million US$), 2013 - 2017
Figure 9?2: Plasma/Serum – Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
Figure 9?3: Urine – Liquid Biopsy Market (Million US$), 2013 - 2017
Figure 9?4: Urine – Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
Figure 9?5: Others – Liquid Biopsy Market (Million US$), 2013 - 2017
Figure 9?6: Others – Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
Figure 10?1: Thermo Fisher – Diagnostics Sales (Million US$), 2013 – 2017
Figure 10?2: Thermo Fisher – Forecast for Diagnostics Sales (Million US$), 2018 – 2024
Figure 11?1: Roche Diagnostics – Diagnostics Sales (Billion US$), 2013 – 2017
Figure 11-2: Roche Diagnostics – Forecast for Diagnostics Sales (Billion US$), 2018 – 2024
Figure 12-1: Bio-Rad Laboratories – Net Sales (Million US$), 2013 – 2017
Figure 12-2: Bio-Rad Laboratories – Forecast for Net Sales (Million US$), 2018 – 2024
Figure 13-1: Biocept – Revenue (Million US$), 2013 – 2017
Figure 13-2: Biocept – Forecast for Revenue (Million US$), 2018 – 2024
Figure 14-1: Biocartis – Net Sales (Thousand US$), 2013 – 2017
Figure 14-2: Biocartis – Forecast for Net Sales (Thousand US$), 2018 – 2024
Figure 15-1: Myriad Genetics – Molecular Diagnostics Revenue (Million US$), 2013 – 2017
Figure 15-2: Myriad Genetics – Forecast for Molecular Diagnostics Revenue (Million US$), 2018 – 2024
Figure 16-1: Genomic Health – Net Sales (Million US$), 2013 – 2017
Figure 16-2: Genomic Health – Forecast for Net Sales (Million US$), 2018 – 2024
Figure 17-1: NeoGenomics Laboratories – Net Sales (Million US$), 2013 – 2017
Figure 17-2: NeoGenomics Laboratories – Forecast for Net Sales (Million US$), 2018 – 2024
Figure 18-1: Qiagen – Revenue (Million US$), 2013 – 2017
Figure 18-2: Qiagen – Forecast For Revenue (Million US$), 2018 – 2024

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *